Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELOS-2: HL036 in Dry Eye Disease
NCT03846453Phase 3Completed
- Sponsor
- HanAll Biopharma
- Start
- Mar 2019
- Primary completion
- Nov 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dry eye disease (DED) comparing 0.25% HL036 with Placebo (2 arms). Primary endpoints: Inferior Corneal Fluorescein Staining Score at Day 57 and Ocular Discomfort Score at Day 57. Started Mar 2019; status: completed.
02
Drugs
tanfanercept
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT03846453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03846453.